Literature DB >> 7054333

Serum levels of antibody to toxoid during tetanus and after specific immunization of patients with tetanus.

P Yeni, C Carbon, F Tremolieres, C Gibert.   

Abstract

Levels of serum antibody to toxoid in patients with tetanus who were immunized with toxoid differed from those in immunized healthy persons in two respects. (1) Base-line levels preceding immunization were higher among patients with tetanus than among young or elderly healthy person, even though the patients with tetanus were evaluated before specific serotherapy. This observation suggests the occurrence of immunostimulation, whether specific or not, by disease during the incubation period. (2) No significant increase in levels of antibody to toxoid was detected among patients with tetanus from the first to the last evaluable serum sample, whereas a significant increase was observed among healthy persons. Specific immunosuppression induced by tetanus toxoid or serotherapy could account for this ineffectiveness of immunization among patients with tetanus, although nonspecific immunosuppression induced by prolonged and severe illness cannot be excluded. Among healthy persons, active immunization is less effective in elderly persons than in young persons [2]. However, age cannot, by itself, account for the type of antibody production observed in patients with tetanus.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7054333     DOI: 10.1093/infdis/145.2.278

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  2 in total

1.  Lower antibody response to tetanus toxoid associated with higher auto-anti-idiotypic antibody in old compared with young humans.

Authors:  E E Arreaza; J J Gibbons; G W Siskind; M E Weksler
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

2.  Epidemiology of tetanus in the Marches Region of Italy, 1992-95.

Authors:  E Prospero; R Appignanesi; M M D'Errico; F Carle
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.